Table 1

Associations between intermediate hyperglycemia and outcomes of interest

IGTIFGHbA1c
Comparison group140 to 199 mg/dL100 to 125 mg/dL110 to 125 mg/dL5.7% to 6.4%6.0% to 6.4%
Referent group<140 mg/dL<100 mg/dL<110 mg/dL<5.7%<6.0%
All-cause mortality1.19 (1.15 to 1.24)1.11 (1.04 to 1.19)1.17 (1.13 to 1.22)1.07 (0.97 to 1.18)1.30 (1.03 to 1.66)
CVD mortality1.21 (1.10 to 1.32)1.14 (1.03 to 1.25)1.20 (1.09 to 1.33)1.20 (0.90 to 1.60)1.07 (0.61 to 1.87)
CVD events1.18 (1.11 to 1.26)1.15 (1.05 to 1.25)1.21 (1.09 to 1.33)1.15 (1.02 to 1.30)1.32 (1.00 to 1.73)
Stroke events1.24 (1.06 to 1.45)1.07 (0.95 to 1.07)1.22 (1.07 to 1.40)1.23 (1.04 to 1.46)1.28 (0.72 to 2.27)
CHD events1.13 (1.05 to 1.21)1.10 (1.02 to 1.19)1.14 (1.06 to 1.22)1.28 (1.13 to 1.46)1.33 (0.74 to 2.38)
Heart failure events5.04 (1.00 to 25.4)0.95 (0.84 to 1.07)1.13 (0.87 to 1.45)
CKD1.15 (0.95 to 1.39)1.09 (1.01 to 1.18)1.08 (0.91 to 1.28)1.32 (1.16 to 1.50)1.50 (1.32 to 1.70)
Retinopathy1.11 (0.84 to 1.45)0.84 (0.61 to 1.14)
  • CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; HbA1c, glycosylated hemoglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.